Identification of miRNA modulators to PARP inhibitor response
Sari Neijenhuis(Institute of Cancer Research), Alan Ashworth(University of California, San Francisco), Ilirjana Bajrami(Institute of Cancer Research), Rowan Miller(University College Hospital), Christopher J. Lord(Institute of Cancer Research)
Cited by 64
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
|Annals of Oncology|2020|478
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
|Cancer Discovery|2017|422
Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma
|Science Translational Medicine|2011|401